Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17488664&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia Blaise D; Vey N; Faucher C; Mohty MHaematologica 2007[Apr]; 92 (4): 533-41Allogeneic stem cell transplantation (allo-SCT) is the most efficient antileukemic treatment for acute myeloblastic leukemia (AML). However, elderly patients can rarely benefit from standard myeloablative allo-SCT because of an unacceptable rate of procedure-related toxicities. This point is critical when considering AML patients in first complete remission. The development of the so-called reduced-intensity conditioning (RIC) regimens appears to decrease allo-SCT-related toxicities, and has emerged as an attractive modality in AML patients not eligible for standard allo-SCT. Such RIC regimens aim primarily to provide the immune graft-versus-leukemia effect while causing little toxicity. Of note, treatment-related toxicity appears to be lower with RIC regimens as compared to standard myeloablative regimens. Nevertheless, toxicity might represent only one aspect of the problem, since AML encompasses a group of chemosensitive diseases, raising concerns that significant reduction of the intensity of the preparative regimen may have a negative impact on long-term leukemic control. Furthermore, no prospective studies have been reported thus far establishing RIC allo-SCT as the preferred option in AML. Investigators are currently faced with a dilemma on how to optimize the potential role of RIC allo-SCT in AML patients, while delivering minimal myeloablation and maximizing allogeneic immunotherapy. The aim of this review is to analyze the available research evidence in this field.|*Hematopoietic Stem Cell Transplantation/mortality/statistics & numerical data[MESH]|Acute Disease[MESH]|Adult[MESH]|Aged[MESH]|Antibodies, Monoclonal/administration & dosage/adverse effects[MESH]|Antilymphocyte Serum/administration & dosage/adverse effects[MESH]|Antineoplastic Agents, Alkylating/administration & dosage/adverse effects[MESH]|Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH]|Bone Marrow Diseases/chemically induced/prevention & control[MESH]|Clinical Trials as Topic/statistics & numerical data[MESH]|Combined Modality Therapy[MESH]|Disease-Free Survival[MESH]|Female[MESH]|Graft vs Leukemia Effect[MESH]|Humans[MESH]|Leukemia, Myeloid/drug therapy/*surgery[MESH]|Lymphocyte Depletion[MESH]|Male[MESH]|Middle Aged[MESH]|Recurrence[MESH]|Remission Induction[MESH]|Survival Analysis[MESH]|T-Lymphocytes[MESH]|Time Factors[MESH]|Transplantation Conditioning/adverse effects/*methods/mortality/statistics & numerical data[MESH]|Transplantation, Homologous[MESH]|Treatment Outcome[MESH]|Vidarabine/administration & dosage/adverse effects/analogs & derivatives[MESH] |